SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients — CARMEN-LC03

Non-small Cell Lung Cancer Metastatic Clinical Trial

Official title:
Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastatic Nonsquamous, Non-small-cell Lung Cancer Patients With CEACAM5-positive Tumors

Status Active, not recruiting

Clinical Trial Summary

Primary Objectives: - Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cut-off date for each given analysis (progression free survival [PFS] and overall survival [OS]) - Study success is defined either on PFS or OS - The primary objective is to determine whether tusamitamab ravtansine improves the progression free survival (PFS) when compared to docetaxel in participants with metastatic non-squamous non-small-cell lung cancer (NSCLC) expressing CEACAM5 greater than or equal to 2+ in intensity in at least 50% of the tumor cell population and previously treated with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor (ICI) - The primary objective is to determine whether tusamitamab ravtansine improves the overall survival (OS) when compared with docetaxel in participants with metastatic non-squamous NSCLC expressing CEACAM5 greater than or equal to 2+ in intensity in at least 50% of the tumor cell population and previously treated with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor. Secondary Objectives: - To compare the objective response rate (ORR) of tusamitamab ravtansine with docetaxel - To compare the health-related quality of life (HRQOL) of tusamitamab ravtansine with docetaxel - To evaluate the safety of tusamitamab ravtansine compared to docetaxel - To assess the duration of response (DOR) of tusamitamab ravtansine as compared with docetaxel

Clinical Trial Description

The expected duration of study intervention for participants who benefit from study intervention may vary, based on progression date; but median expected duration of study per participant is estimated as median 9 months in docetaxel arm (1 month for screening, 4 months for treatment, and 4 months for the EOT and follow-up visits) and 12.5 months in SAR408701 arm (1 month for screening, 6.5 months for treatment, and 5 months for end of treatment follow-up). ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Non-small Cell Lung Cancer Metastatic

Clinical Trial Details

NCT number	NCT04154956
Study type	Interventional
Source	Sanofi
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	February 6, 2020
Completion date	August 26, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01523340` - A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
Recruiting	`NCT03956641` - Evolution of the Physical Condition in Treated Cancer Patients	N/A
Active, not recruiting	`NCT02035683` - PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy	N/A
Completed	`NCT01848613` - Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC	Phase 4
Suspended	`NCT01320501` - Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer	Phase 4
Terminated	`NCT01471964` - Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer	Phase 1/Phase 2
Recruiting	`NCT06127940` - K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation	Phase 1
Terminated	`NCT04069936` - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC	Phase 2
Terminated	`NCT03445000` - ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer	Phase 2
Terminated	`NCT03386929` - Survival Prolongation by Rationale Innovative Genomics	Phase 1/Phase 2
Recruiting	`NCT02922764` - A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer	Phase 1
Terminated	`NCT01574300` - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Active, not recruiting	`NCT04646824` - Almonertinib With Chemotherapy in mEGFR NSCLC	Phase 2
Completed	`NCT01966003` - Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer	Phase 3
Recruiting	`NCT03656094` - Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors	Phase 2
Terminated	`NCT01348126` - Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer	Phase 2/Phase 3
Active, not recruiting	`NCT03469960` - Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr	Phase 3
Recruiting	`NCT05919264` - FOG-001 in Locally Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT04793815` - Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)	N/A
Terminated	`NCT01380795` - Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas	Early Phase 1